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ABSTRACT
Background
The efficacy of statin therapy in patients with established chronic heart failure (CHF) is a
subject of much debate.
Methods and Findings
We conducted three systematic literature searches to assess the evidence supporting the
prescription of statins in CHF. First, we investigated the participation of CHF patients in
randomized placebo-controlled clinical trials designed to evaluate the efficacy of statins in
reducing major cardiovascular events and mortality. Second, we assessed the association
between serum cholesterol and outcome in CHF. Finally, we evaluated the ability of statin
treatment to modify surrogate endpoint parameters in CHF.
Using validated search strategies, we systematically searched PubMed for our three queries.
In addition, we searched the reference lists from eligible studies, used the ‘‘see related articles’’
feature for key publications in PubMed, consulted the Cochrane Library, and searched the ISI
Web of Knowledge for papers citing key publications.
Search 1 resulted in the retrieval of 47 placebo-controlled clinical statin trials involving more
than 100,000 patients. CHF patients had, however, been systematically excluded from these
trials. Search 2 resulted in the retrieval of eight studies assessing the relationship between
cholesterol levels and outcome in CHF patients. Lower serum cholesterol was consistently
associated with increased mortality. Search 3 resulted in the retrieval of 18 studies on the
efficacy of statin treatment in CHF. On the whole, these studies reported favorable outcomes
for almost all surrogate endpoints.
Conclusions
Since CHF patients have been systematically excluded from randomized, controlled clinical
cholesterol-lowering trials, the effect of statin therapy in these patients remains to be
established. Currently, two large, randomized, placebo-controlled statin trials are under way to
evaluate the efficacy of statin treatment in terms of reducing clinical endpoints in CHF patients
in particular.
The Editors’ Summary of this article follows the references.
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The efﬁcacy of 3-hydroxy-3-methylglutaryl coenzyme-A
reductase inhibitors, or statins, in reducing morbidity and
mortality in patients with documented coronary artery
disease (CAD), or at risk of developing it, has been
overwhelmingly and indisputably proven during the past
decade [1–15]. However, it is unclear whether statin
treatment is also beneﬁcial in patients with established
chronic heart failure (CHF) [16,17]. To investigate the
strength of the evidence supporting statin treatment in
patients with CHF, three systematic literature searches were
carried out. The objectives of these searches were as
follows: (i) to assess the participation of CHF patients in
randomized, placebo-controlled clinical trials designed to
evaluate the efﬁcacy of statin treatment in reducing major
cardiovascular events and death, (ii) to determine the
relationship between cholesterol levels and outcome in
patients with established CHF, and (iii) to assess the
reported efﬁcacy parameters and results of statin treatment
in patients with established CHF.
Methods
This study and reporting was performed adhering to the
QUOROM [18] statement when possible (see Protocol S1).
Literature Search
The search to identify all potentially relevant studies was
initiated using search tools provided by PubMed (http://www.
ncbi.nlm.nih.gov/entrez/query/static/clinical.shtml; used July
2005). These search tools have recently been validated by
Haynes et al. as optimizing retrieval [19]. The scope ﬁlters
employed were all set to ‘‘broad, sensitive search’’ as
recommended for research applications. We included papers
published in all languages. We constructed one query per
objective (see Protocol S2). In addition, we consulted with
experts, searched our own ﬁles, reviewed reference lists from
eligible studies, used the ‘‘see related articles’’ feature for key
publications in PubMed, consulted the Cochrane Library, and
searched the ISI Web of Knowledge (http://scientiﬁc.thomson.
com/webofknowledge) for publications that cited key pub-
lications.
CHF Patients in Clinical Statin Trials
The ﬁrst objective was to discover whether CHF patients
were included in randomized clinical trials in which the
efﬁcacy of statin therapy in reducing major adverse cardiac
events or death was either a primary or secondary
endpoint. All randomized, placebo-controlled clinical trials,
including those still ongoing, were included. Exclusion
criteria relating to CHF (New York Heart Association
[NYHA] class and left ventricular ejection fraction [LVEF])
were recorded.
Cholesterol and CHF
The second objective was to assess the association between
cholesterol levels and outcome in patients with established
CHF. We anticipated retrieving predominantly small-scale,
post hoc observational studies using various methodologies
and analyzing different cholesterol cutoff values. For this
reason we did not assess the magnitude of the effect of
cholesterol levels on CHF prognosis.
Statin Treatment in CHF
The third objective was to assess the clinical evidence
established in patients with CHF. All studies that aimed to
evaluate statin treatment speciﬁcally in patients with estab-
lished CHF were included. All reported efﬁcacy parameters
and study designs were assessed to estimate the strength of
the clinical evidence. Case reports and serial case reports
were excluded. Studies that investigated the effect of statins
on the incidence of CHF in non-CHF populations were also
excluded.
Methods of Analysis
The results of the data extraction and assessment were
summarized in structured tables.
Results
CHF Patients in Statin Trials
The electronic search retrieved 1,329 possibly relevant
papers about CHF patients in statin trials. Of these, 47
randomized, controlled trials (including six ongoing) pub-
lished between 1990 and 2005 fulﬁlled the eligibility criteria.
Details of those papers excluded are shown in Figure 1A. In
the 41 completed trials, a total of 106,167 patients were
randomized to statin treatment or placebo. There were 14
primary prevention trials, 25 secondary prevention trials, and
two trials that combined primary and secondary prevention
(Table 1). Eighteen trials, with a total of 48,623 patients (46%
of the total for all 41 trials), excluded all CHF patients. One
trial excluded patients with LVEF less than 40% (n ¼ 695,
0.7%), three trials excluded patients with LVEF less than 30%
(n ¼ 2,970; 3%), and one excluded patients with LVEF less
than 35% (n ¼ 460; ,0.01%). Four trials excluded patients
with NHYA III or higher (n ¼ 10,855; 10%), four excluded
patients with ‘‘severe’’ heart failure (21,327; 20%), and two
trials excluded patients with symptomatic heart failure (n ¼
13,173; 12%). Eight papers provided no information in either
the methodology or the baseline characteristics on whether
CHF patients had been included (n ¼ 8,064; 8%). The
Cholesterol and Recurrent Events (CARE) trial excluded
symptomatic heart failure, but reported a subgroup analysis
of 706 patients with decreased LVEF (26%–40%). Statins
were equally effective in patients with and without decreased
LVEF [4]. Of the six ongoing trials, two are speciﬁcally
designed to include CHF patients and will be discussed below
[20,21].
Cholesterol and CHF
The electronic search retrieved 632 possibly relevant
papers about cholesterol and CHF. Eight papers describing
ten independent patient populations (n ¼ 3,879 in total) and
published between 1998 and 2005 fulﬁlled the eligibility
criteria (Figure 1B). Seven CHF populations were studied
retrospectively (n ¼ 2,837; 73%) and three populations were
studied prospectively (n ¼ 1,039; 27%). Both ischemic and
non-ischemic cardiomyopathies were studied, and mortality
was the outcome parameter in all but one study (n¼58; 1%).
In 1998, Vredevoe et al. were the ﬁrst to report that lower
total cholesterol was associated with increased mortality in
patients with advanced, idiopathic CHF [22]. Two studies
sought to identify the optimum cholesterol cutoff value to
predict mortality. In the study carried out by Horwich et al.,
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sis, the optimum cutoff for total cholesterol in predicting
mortality in CHF patients was 4.9 mmol/l (190 mg/dl), with a
sensitivity of 70% for predicting mortality at 5 y [23].
Similarly, Rauchhaus et al. reported that the optimum cutoff
value was 5.2 mmol/l (200 mg/dl) for predicting mortality at
both 1 y (sensitivity 80%, speciﬁcity 63%) and 3 y (sensitivity
62%, speciﬁcity 74%). In this study, the chance of survival
increased by approximately 25% for each millimoles/liter
increment in total cholesterol (relative risk 0.75 [95%
conﬁdence interval (CI) 0.63–0.90]) [24]. On the other hand,
a recent article by Christ et al. questioned the prognostic
value of total cholesterol in patients with idiopathic dilated
cardiomyopathy. Univariately, decreased total cholesterol was
only a moderate predictor, and lost its signiﬁcance after
adjustment for increased left ventricular end-diastolic diam-
eter, reduced LVEF, and increased NHYA class for the
combined endpoint of death or heart transplantation (p ¼
0.34), and was borderline signiﬁcant for the endpoint of
death (p ¼ 0.07; Table 2) [25]. Overall, results from eight
patient populations and involving a total of 3,341 patients
(86%) reported low cholesterol to be an independent
predictor associated with mortality. Since methodology and
categorization varied considerably among the reported
populations, pooling of the results to determine the
magnitude (hazard ratio [HR]) was inappropriate.
Statin Treatment in CHF
The electronic search retrieved 263 papers about statin
treatment in CHF. Eighteen papers reporting efﬁcacy
parameters for statin treatment in CHF were included
(Figure 1C). Outcome parameters differed considerably
(Table 3) and did not allow pooling of data. Only one study,
involving 24 patients, reported a reduction of coenzyme Q10,
which is a possible adverse outcome [26]. All other studies
reported favorable outcomes for almost all surrogate
endpoint parameters or post hoc analyses of major adverse
cardiac events or mortality (Table 3). Three studies had a
prospective, randomized, placebo-controlled design involv-
ing a total of 104 patients. All these studies reported
surrogate endpoints, and none had a single prespeciﬁed
primary outcome parameter. One of the most noteworthy
prospective studies was performed in idiopathic dilated
cardiomyopathy [27]. Fifty-one patients were randomly
assigned to simvastatin (up to 10 mg/d) or placebo. Using
M-mode echocardiography with 2-D monitoring before and
after 14 wk of treatment, Node et al. demonstrated
improvement in functional capacity in statin-treated pa-
tients. In the statin group, 39.1% of patients had an
improved functional class and 4.3% deteriorated. In con-
trast, in the placebo group 16% of patients improved and
12% deteriorated (p , 0.01). Another prospective, double-
blind study randomized patients with non-ischemic dilated
Figure 1. Flow Diagrams of Study Selection
(A) Selection of studies about the handling of CHF patients in placebo-controlled statin trials.
B) Selection of studies about the association between cholesterol levels and mortality in CHF patients.
(C) Selection of studies containing original data on statin treatment in patients with established CHF.
DOI: 10.1371/journal.pmed.0030333.g001
PLoS Medicine | www.plosmedicine.org August 2006 | Volume 3 | Issue 8 | e333 1405
Statins in Chronic Heart Failurecardiomyopathy to cerivastatin (0.4 mg/d) or placebo [28].
Quality of life and exercise capacity increased signiﬁcantly
in the statin-treated patients. In addition, there was a trend
towards increased LVEF and improved endothelial function.
Recently, Landmesser et al. demonstrated improvement of
endothelial function in CHF patients randomized to
simvastatin (10 mg/d), but not in patients randomized to
ezetimibe (10 mg/d) [29]. This suggests that improvement of
endothelial function is independent of low-density lip-
oprotein cholesterol reduction.
Table 1. Placebo-Controlled Statin Trials and CHF Patients
Study, Date Number of
Patients
Intervention Prevention of Cardiovascular
Morbidity and Mortality
CHF Patients
Brown et al., 1990 [50]
a 120 Lovastatin (40 mg) Primary Excluded
PMSGCRP, 1993 [1] 1,062 Pravastatin (20 mg) Primary Excluded
MARS, 1993 [51]
a 270 Lovastatin (80 mg) Secondary Not reported
ACAPS, 1994 [52]
a 919 Lovastatin (20–40 mg) Primary Excluded
CCAIT, 1994 [53]
a 331 Lovastatin (36 mg) Secondary Excluded
PLAC II, 1994 [54]
a 151 Pravastatin (20–40 mg) Secondary Excluded uncontrolled heart failure
MAAS, 1994 [55]
a 381 Simvastatin (20 mg) Secondary Excluded
4S, 1994 [2] 4,444 Simvastatin (10–40 mg) Secondary Excluded
LSRTSG, 1994 [56]
a 404 Lovastatin (80 mg) Secondary Not excluded (mean LVEF 60% 6 12%)
KAPS, 1995 [57]
a 447 Pravastatin (40 mg) Primary/secondary Not reported
REGRESS, 1995 [58]
a 885 Pravastatin (40 mg) Secondary Excluded clinical congestive heart failure after
medical management and patients requiring
diuretics (ejection fraction , 0.3 if performed)
PLAC I, 1995 [59]
a 408 Pravastatin (40 mg) Secondary Excluded LVEF , 30%
WOSCOPS, 1995 [3] 6,595 Pravastatin (40 mg) Primary Excluded
CARE, 1996 [4] 4,159 Pravastatin (40 mg) Secondary Excluded symptomatic CHF
LCAS, 1997 [60]
a 429 Fluvastatin (40 mg) Secondary Not reported
CIS, 1997 [61]
a 254 Simvastatin (40 mg) Secondary Not reported
PREDICT, 1997 [62]
a 695 Pravastatin (40 mg) Secondary Excluded LVEF , 40%
AFCAPS/TexCAPS, 1998 [5] 6,605 Lovastatin (20–40 mg) Primary Excluded
LIPID, 1998 [6] 9,014 Pravastatin (40 mg) Secondary Excluded symptomatic CHF
FLARE, 1999 [63]
a 1,054 Fluvastatin (80 mg) Secondary Not reported
LiSA, 1999 [64]
a 365 Fluvastatin (40 mg) Secondary Excluded NHYA III/IV
MIRACL, 2001 [7] 3,086 Atorvastatin (80 mg) Secondary Excluded NYHA IIIb/IV; no difference in
worsening heart failure
SCAT 2000 [65]
a 460 Simvastatin (40 mg) Secondary Excluded LVEF , 35%
BCAPS, 2001 [66]
a 793 Fluvastatin (40 mg) Primary Excluded history of myocardial
infarction or angina pectoris
Den Hartog et al., 2001 [67]
a 100 Pravastatin (40 mg) Secondary (acute coronary syndromes) Excluded severe heart failure
GREACE, 2002 [11] 1,600 Atorvastatin (24 mg) Secondary Excluded NYHA III/IV
FLORIDA, 2002 [68]
a 540 Fluvastatin (80 mg) Secondary Excluded severe heart failure
MRC/HPS, 2002 [8] 20,536 Simvastatin (40 mg) Secondary Excluded severe heart failure
LIPS, 2002 [9] 1,677 Fluvastatin (80 mg) Secondary Excluded LVEF , 30%
PROSPER, 2002 [10,69] 5,804 Pravastatin (40 mg) Primary/secondary Excluded NYHA III/IV; no difference
in CHF hospitalization
ALLHAT-LLT, 2002 [12] 10,355 Pravastatin (20–40 mg) Primary Excluded
ASCOT-LLA, 2003 [13] 10,305 Atorvastatin (10 mg) Primary Excluded
ALERT, 2003 [14] 2,102 Fluvastatin Primary (renal transplant patients) Not reported
CARDS, 2004 [15] 2,838 Atorvastatin (10 mg) Primary Excluded
O’Rourke et al., 2004 [70]
a 97 Fluvastatin (40 mg) Secondary (heart transplant patients) Excluded
PACT, 2004 [71] 3,408 Pravastatin (20–40 mg) Secondary Not reported
Durazzo et al., 2004 [72] 100 Atorvastatin (20 mg) Secondary (vascular surgery patients) Not reported
PREVEND-IT, 2004 [73] 864 Pravastatin (40 mg) Primary Excluded
Beishuizen et al., 2004 [74]
a 250 Cerivastatin (0.4 mg),
simvastatin (20 mg)
b
Primary Excluded
4D study, 2005 [75] 1,255 Atorvastatin (20 mg) Primary Excluded
St. Francis Heart Study, 2005 [76] 1,005 Atorvastatin (20 mg) þ
vitamin C (1 g) þ
vitamin E (1,000 U)
Primary Excluded
SPARCL, ongoing [77] 4,732 Atorvastatin (80 mg) Secondary Excluded
FACS trial, ongoing [78]
a 1,000 Fluvastatin (80 mg) Secondary (acute coronary syndrome) Not reported
AURORA, ongoing [79] 2,750 Rosuvastatin (10 mg) Primary (end-stage renal disease) Not reported
SHARP, ongoing [80] ;9,000 Simvastatin (20 mg) 6
ezitimibe (10 mg)
Primary (chronic kidney disease) Excluded history of myocardial infarction
GISSI-HF, ongoing [21] ;5,000 Rosuvastatin (10 mg) Secondary Included NYHA II–IV
CORONA, ongoing [81] ;5,000 Rosuvastatin (10 mg) Secondary Included NYHA II–IV and/or LVEF , 40%
aMajor adverse cardiac events/mortality was not primary endpoint.
bWhen cerivastatin was withdrawn from the market, it was replaced by simvastatin (20 mg) without deblinding the study.
DOI: 10.1371/journal.pmed.0030333.t001
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are currently under way, together involving in excess of
10,000 patients [20,21]. The Controlled Rosuvastatin multi-
national Study in Heart Failure (CORONA) will enroll about
4,950 patients with chronic, symptomatic systolic heart
failure due to CAD [20]. The primary outcome is the
composite endpoint of cardiovascular death or nonfatal
myocardial infarction or nonfatal stroke. The Gruppo
Italiano per lo Studio della Sopravvivenza nell’Infarto
Miocardico (GISSI) heart failure trial will enroll approx-
imately 7,000 patients to be randomized to n-3 polyunsatu-
rated fatty acids or matching placebo, and if there is no clear
indication for cholesterol-lowering therapy, patients will be
further randomized to receive rosuvastatin or matching
placebo [21]. The GISSI heart failure trial has two co-primary
endpoints, namely all-cause mortality and the combined
endpoint of all-cause mortality or cardiovascular hospital-
izations. These two trials will formally assess statin treatment
in CHF.
Discussion
Although more than 100,000 patients have been studied in
clinical trials evaluating the efﬁcacy of statin treatment
compared to placebo in primary and secondary prevention of
cardiovascular morbidity and mortality, this investigation has
revealed that the vast majority of published statin trials
excluded patients with LVEF below 40% or NYHA III/IV. In
Table 2. Cholesterol and CHF
Study Type of CHF Patients
(n)
Study
Design
Duration
(Years)
Outcome
Parameter
Multivariate Analysis
Adjusted Parameters
Results (Multivariate)
Vredevoe et al., 1998 [22] IDCM 109 Retrospective 1 Mortality Anergy, ACEi use, age,
LVEF, right atrial pressure,
cardiac output, pulmonary
capillary wedge pressure,
serum sodium, BMI
HR 0.674 (95% CI 0.539–0.848)
per milligrams/deciliter increase
in total cholesterol
Vredevoe et al., 1998 [22] Ischemic 113 Retrospective 1 Mortality Anergy, ACEi use, age,
LVEF, right atrial pressure,
cardiac output, pulmonary
capillary wedge pressure,
serum sodium, BMI
HR 1.001 (95% CI 0.970–1.032)
per milligrams/deciliter increase
in total cholesterol
Richartz et al., 1998 [82] Left ventricular
assist device
implantation in
IDCM and ischemic
45 Retrospective 0.4 Mortality Not adjusted Serum cholesterol , 2.6 mmol/l
(,100 mg/dl) sensitivity (death)
100%; cholesterol . 3.1 mmol/l
(.120 mg/dl) specificity
(survival) 87%
Rauchhaus et al., 2000 [83] 62% ischemic, 38%
non-ischemic
58 Prospective 1 Event-free Peak VO2 , 14 ml/kg/min,
NYHA class III/IV, presence
of cardiac cachexia
Serum cholesterol , 5.2 mol/l
(,200 mg/dl) RR 3.5 (95%
CI 1.1–11.0)
Horwich et al., 2002 [23] 48% ischemic,
40% idiopathic
1,134 Retrospective 5 Mortality Age, sex, LVEF, BMI, ACEi use,
lipid-lowering medication,
pulmonary capillary wedge
pressure, blood urea
nitrogen, creatinine, albumin,
hypertension, diabetes,
smoking history
RR 0.996 (95% CI 0.994–0.999)
per milligrams/deciliter increase
in total cholesterol
Rauchhaus et al., 2003 [24] 62% ischemic,
38% DCM
114 Retrospective 3 Mortality Soluble tumor necrosis factor
receptor I, LVEF, peak VO2
HR 0.61 (95% CI 0.11–0.85)
per millimoles/liter increase
in cholesterol
Rauchhaus et al., 2003 [24] 60% ischemic,
40% DCM
303 Retrospective 3 Mortality Cachexia, LVEF, peak VO2,
etiology, NYHA class, age
HR 0.75 (95% CI 0.63–0.90)
per millimoles/liter increase
in cholesterol
Mozaffarian et al., 2004 [84] 61% ischemic 1,019 Retrospective 1.3 Mortality Age, gender, diabetes,
smoking status, heart
failure etiology, NYHA
class, LVEF, systolic blood
pressure, amlodipine,
allopurinol, sodium, blood
urea nitrogen, creatinine,
hematocrit, white blood
cell count, lymphocyte
count
Low cholesterol associated
with mortality; not quantified
Rosolova et al., 2005 [85] 55% CAD 559 Prospective 4 Mortality Not adjusted Low cholesterol associated
with mortality; not quantified
Christ et al., 2005 [25] 100% IDCM 422 Prospective 3.5 Mortality Left ventricular end-diastolic
dimension, NYHA class I–III,
LVEF
HR 0.84 (95% CI 0.70–1.01)
per millimoles/liter increase
in cholesterol (p ¼ 0.07)
ACEi, ACE inhibitor; BMI, body mass index; DCM, dilated cardiomyopathy; IDCM, idiopathic dilated cardiomyopathy; RR, relative risk.
DOI: 10.1371/journal.pmed.0030333.t002
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Statins in Chronic Heart Failureaddition, we report that in CHF patients, instead of high-
serum cholesterol levels, low-serum cholesterol levels have
been consistently associated with increased mortality rates.
Finally, this study has revealed that although most studies
assessing the effect of statins in CHF are encouraging, they
only report surrogate efﬁcacy parameters or are based on
secondary analyses.
Theoretical Considerations for Statin Treatment in CHF
Patients
We conclude that statin treatment in CHF has never been
assessed in a large clinical trial setting, which is the gold
standard for clinical evidence (Table 1). In view of this, the
question is to what extent can the results of studies
performed in other patient groups be extrapolated to CHF
populations?
There are several theoretical considerations that argue in
favor or against statin treatment in CHF. The most relevant
arguments against statin therapy are the endotoxin lip-
oprotein hypothesis, the coenzyme Q10 (ubiquinone) hypoth-
esis, and the selenoprotein hypothesis. The endotoxin
lipoprotein hypothesis is related to lower cholesterol levels
and will be discussed below. The ubiquinone hypothesis
reasons that the inhibition of mevalonate synthesis by statins
decreases the production of ubiquinone (coenzyme Q10).
Ubiquinone is involved in the production of ATP and
therefore in meeting the metabolic demands of cells [30].
Another fundamental characteristic of ubiquinone is its
antioxidant (free-radical-scavenging) properties. The seleno-
protein hypothesis postulates that statins interfere with the
enzymatic isopentenylation of selenocysteine tRNA and
prevent its maturation to a functional tRNA molecule,
resulting in a decrease in available selenoproteins [31].
Individuals with statin-induced myopathy have clinical and
pathological features similar to those of syndromes associated
with severe selenoprotein deﬁciency [31].
The potential beneﬁcial effects of statin treatment in CHF
include improved vascular function, improved neurohormo-
nal status, and decreased development of left ventricular
hypertrophy. Statin treatment has been shown to favorably
affect endothelial function [29], as well as increasing capillary
density [32] and circulating endothelial progenitor cells [33],
and slowing the progression of coronary atherosclerosis [34].
In addition, statins also modify the major neurohormonal
systems involved in CHF, decreasing responsiveness to
angiotensin II, for example [35]. Statins also inhibit the
beta-adrenergic receptor activation of Rac1 and conse-
quently apoptosis [36]. Finally, by blocking the synthesis of
mevalonate, statins reduce the development of left ventric-
ular hypertrophy [37].
Cholesterol in CHF
In middle-aged persons, hypercholesterolemia is a well-
known risk factor predicting the development of CAD and
long-term all-cause mortality. This association is, however,
controversial in elderly patients and those with a wide range
of chronic and acute diseases [38–40]. In the Framingham
study, dyslipidemia initially appeared to be a risk factor for
the development of CHF [41]. However, in a more detailed
analysis of the same Framingham database, the association
between total cholesterol and all-cause mortality was found to
be positive at 40 y, negligible at 50–70 y, and negative at age
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Statins in Chronic Heart Failure80 y and above [42]. In this context, it is important to note
that the incidence and prevalence of CHF rises steeply with
age, and that almost 80% of CHF patients are over 65 y of age.
Despite these observations, however, the evidence from
clinical trials proves that statin treatment is effective in
elderly patients [43]. The Pravastatin in Elderly Individuals at
Risk of Vascular Disease (PROSPER) trial extended the
clinical evidence supporting statin treatment to elderly
patients (.70 y) at high risk of developing cardiovascular
disease and stroke [10].
Several studies have addressed the relation and relevance
of serum cholesterol levels to outcome in CHF patients in
particular, and the results consistently suggest that lower
cholesterol is associated with increased mortality (Table 2).
More speciﬁcally, for each millimoles/liter decrease in total
cholesterol, mortality increases by 25% [23,24]. This
phenomenon of ‘‘reverse epidemiology’’ in CHF is not
unique for cholesterol levels, and also exists for body mass
index and blood pressure [44]. Nevertheless, the above-
mentioned studies are observational studies and therefore
of limited value. Although most studies are corrected for
several indicators, such as nutritional status and cachexia,
they may have been inadequately adjusted for other
confounders. Lower cholesterol may mark an end-stage
disease epiphenomenon, due to reduced hepatic cholester-
ol synthetic capacity. The endotoxin lipoprotein hypoth-
esis, however, offers a plausible explanation for the
observed relationship. This hypothesis postulates that
higher levels of cholesterol might be beneﬁcial in CHF
because of the ability of cholesterol to modulate inﬂam-
matory immune function [45]. CHF patients have increased
serum cytokine levels, which might be linked to increased
endotoxin levels [46]. Circulating cholesterol- and trigly-
ceride-rich lipoproteins are natural nonspeciﬁc buffers of
endotoxins. They have the capacity to bind and detoxify
bacterial lipopolysaccharides. In parallel with raised lip-
opolysaccharide plasma concentrations, patients with
edematous and severe CHF show substantial immune
activation [46]. Episodes of endotoxemia may occur, and
reducing lipoproteins could adversely affect lipopolysac-
charide bioactivity modiﬁcation [45].
Clinical Evidence Supporting Statin Therapy in CHF
Several post hoc subgroup analyses of data from large
clinical statin trials have been published, and have examined
the effects of statins in CHF or on the development of CHF
[2,4,10,47,48]. One recent study, the Treating to New Targets
(TNT) study involving 10,001 CAD patients, investigated the
efﬁcacy of 80 mg versus 10 mg of atorvastatin (no placebo
arm). In this study, high-dose statin therapy was associated
with a 26% decrease in hospitalization for congestive heart
failure, which was a predeﬁned secondary efﬁcacy outcome
parameter (HR 0.74 [95%CI 0.59–0.96], p ¼ 0.01) [49].
Statin therapy has been associated with reduced mortality
in observational studies (Table 3). Nevertheless, the effects
of statin use in CHF currently reported in the literature do
not prove causality, and are susceptible to considerable
confounders and biases. First, the single largest confounder
in nonrandomized studies is probably the patient character-
istics that are related to the physicians’ decision to
prescribe a statin. Second, some of these CHF studies were
conducted at a time when beta-blockers and spironolactone
were not generally used in severe heart failure. Third, most
of the patients receiving statin treatment at discharge were
on statin treatment before inclusion in the study, which
further complicates the analyses. Finally, although statin
therapy seems to reduce new onset of heart failure, this
reduction could be related to effects on reduction of
recurrent myocardial infarction and subsequent CHF,
rather than the development of CHF without recurrent
infarctions.
There are limited data on the effects of statin treatment in
patients with established CHF (Table 3). At present, the
available CHF trials appear encouraging, however, and their
results warrant conﬁrmation in large clinical trials.
Strengths and Limitations
This paper is the ﬁrst, to our knowledge, to systematically
review the available data on the use of statin treatment in
CHF patients. Limitations of the current study include the
potential publication biases of the retrieved studies. Obser-
vational studies and post hoc analyses of clinical trials
investigating the correlation between cholesterol levels and
outcome in patients with CHF are exploratory in nature and
may be more likely to be published if an association is found.
Likewise, the published small-scale prospective studies
evaluating statins speciﬁcally in CHF patients might also
have suffered from publication bias since negative studies
might have been considered underpowered.
Conclusions
Despite widespread clinical use of statins for hypercholes-
terolemia and prevention of CAD, there is a paucity of data
on the effects of statins on clinical outcome in CHF.
Currently, the available experimental, post hoc, and obser-
vational data and theoretical considerations are conﬂicting.
On the one hand, three lines of evidence point towards
statins having a harmful effect in CHF. First, lower
cholesterol levels have repeatedly been related to a poorer
outcome in CHF patients. This may be related to the function
of cholesterol as a scavenger for cardiodepressive and
harmful endotoxins. Second, statins in CHF may adversely
affect mitochondrial function through inhibition of ubiqui-
none. Third, statins may decrease selenoproteins, which
could result in decreased myocardial function. On the other
hand, evidence of beneﬁcial effects of statin treatment in
CHF is accumulating. First, beneﬁcial effects of statins
demonstrated in non-CHF conditions, e.g., on vascular
function, atherosclerosis, and left ventricular hypertrophy,
might also be beneﬁcial in CHF. Second, clinical knowledge
regarding statin treatment in CHF is generally favorable,
although it is primarily based on retrospective post hoc
studies performed within the scope of large clinical trials and
on small prospective studies with surrogate endpoints.
Statin treatment in established CHF has never been
formally assessed in a large clinical trial, the gold standard
for clinical evidence. Therefore, there are currently no
reliable clinical data on the efﬁcacy of statins in CHF. Two
large clinical trials are, however, now under way to clarify
the effects of statin treatment in CHF [20,21]. These two
studies will provide a more deﬁnite answer to whether or
not we should initiate statin treatment in patients with
established CHF.
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Statins in Chronic Heart FailureEditors’ Summary
Background. When medical researchers test a drug—or some other
treatment—for a particular medical condition, they often decide not to
include in their study anyone who has, in addition to the disease they are
interested in, certain other health problems. This is because including
patients with two or more conditions can complicate the analysis of the
results and make it hard to reach firm conclusions. However, excluding
patients in this way can result in uncertainty as to whether treatments
are effective for anyone who suffers from the disease in question, or just
for people like those who took part in the research.
A great deal of research has been conducted with drugs known as
statins, which lower cholesterol levels in the blood. (A raised level of
cholesterol is known to be a major risk factor for cardiovascular disease,
which causes heart attacks and strokes.) As a result of this research,
statins have been accepted as effective and safe. They are now, in
consequence, among the most commonly prescribed medicines. Heart
failure, however, is not the same thing as a heart attack. It is the name
given to the condition where the muscles of the heart have become
weakened, most often as a result of aging, and the heart becomes
gradually less efficient at pumping blood around the body. (Some
people with heart failure live for many years, but 70% of those with the
condition die within ten years.) It is common for people with
cardiovascular disease also to have heart failure. Nevertheless, some
researchers who have studied the effects of statins have made the
decision not to include in their studies any patients with cardiovascular
disease who, in addition, have heart failure.
Why Was This Study Done? The researchers in this study were aware
that patients with heart failure have often been excluded from statin
trials. They felt it was important to assess the available evidence
supporting the prescription of statins for such patients. Specifically, they
wanted to find out the following: how often have patients with heart
failure been included in statin trials, what evidence is available as to
whether it is beneficial for patients with heart failure to have low
cholesterol, and what evidence is there that prescribing statins helps
these patients?
What Did the Researchers Do and Find? They did not do any new work
involving patients. Instead, they did a very thorough search for all
relevant studies of good quality that had already been published and
they reviewed the results. ‘‘Randomized clinical trials’’ (RCTs) are the
most reliable type of medical research. The researchers found there had
been 47 such trials (involving over 100,000 patients) on the use of statins
for treating cardiovascular disease, but all these trials had excluded heart
failure patients. They found eight studies (which were not RCTs) looking
at cholesterol levels and heart failure. These studies found, perhaps
surprisingly, that death rates were higher in those patients with heart
failure who had low cholesterol. However, they also found 18 studies
(again not RCTs) on the use of statins in patients with heart failure. These
18 studies seemed to suggest that statins were of benefit to the patients
who received them.
What Do These Findings Mean? The evidence for or against prescribing
statins for people with heart failure is limited, conflicting, and unclear.
Further research involving RTCs is necessary. (Two such trials are known
to be in progress.)
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030333.
  General information about statins is available from the Web site of
Patient UK
  The American Heart Association Web site is a good source of
information about all types of heart disease, including heart attacks
and heart failure
  For a definition of randomized controlled trials see Wikipedia, a free
online encyclopedia that anyone can edit
  More detailed information about the quality of evidence from medical
research may be found in the James Lind Library
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